Canakinumab in preventing progression of high-risk CCUS to myeloid neoplasms: a Phase II study

Uma Borate, MD, The Ohio State University, Columbus, OH, outlines a Phase II study (NCT05641831) in which patients with high-risk clonal cytopenia of unknown significance (CCUS) randomly received the IL-1β antibody canakinumab or placebo. This study aims to modify the natural history of high-risk CCUS and prevent progression to malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

• #education
• #speaker_uma_borate
• #event_ash_2023
• #format_interview
• #institution_the_ohio_state_university
• #subject_acute_myeloid_leukemia
• #subject_leukemia
• #subject_myelodysplastic_syndromes
• #field_treatment
• #field_immuno_oncology
• #medicines_canakinumab
• #medicines_antibodies
• #il_1
• #ccus
• #clonal_cytopenia_of_unknown_significance
• #clonal_mutations
• #variant_allele_frequency
• #toxicity
• #mds
• #aml